
Commentary|Videos|December 10, 2024
Dr Lee on Real-World Early Outcomes With Second-Line Axi-Cel for R/R LBCL
Author(s)Dasom (Caroline) Lee, MD
Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Advertisement
Dasom (Caroline) Lee, MD, Hematology and Medical Oncology Fellowship Program, Stanford Medicine, Stanford Health Care, discusses real-world early outcomes of treatment with second-line axicabtagene ciloleucel (axi-cel; Yescarta) in relapsed/refractory large B-cell lymphoma. Lee and colleagues shared these results in a presentation at the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































